Publications

• Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]

  F. Griesinger, S. Radke, A. Lüers, B. Deschler-Baier, M. Kimmich, M. Sebastian, C. Schulz, W. Brugger, R. Wiewrodt, R. Pirker, M. Früh, O. Gautschi, J. Wolf

  PMID: 30408830 Show Details link to full text
  Study

  Pneumologie 30408830

  Year

  2018

  Keywords

  • lung cancer
  • EGFR-TKI resistance
  • Osimertnip
  • oncology

• Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study

  J. C. Becker, J. C. Hassel, C. Menzer, K. C. Kähler, T. K. Eigentler, F. E. Meier, C. Berking, R. Gutzmer, P. Mohr, F. Kiecker, M. Kaatz, C. Windemuth-Kieselbach, C. Lorenz-Schlüter, L. Zimmer, S.Ugurel, Dirk Schadendorf, and German Dermatooncology Group (DeCOG/ADO)

  PMID: Show Details link to full text
  Study

  ADMEC-O

  Year

  2018

  Keywords

  • Merkel cell carcinoma
  • skin cancer
  • ipilimumab
  • oncology

• Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries

  G. Oskay-Özcelik, S. Alavi, R. Richter, M. Keller, R. Chekerov, S. C. Cecere, G. Cormio, F. Joly, J. E. Kurtz, A. du Bois, M. Maciejewski, M. Jedryka, I. Vergote, E. Van Nieuwenhuysen, A. Casado, C. Mendiola, P. Achimas-Cadariu, C. Vlad, D. Reimer, A. G. Zeimet, M. Friedlander, J. Sehouli

  PMID: 29415128 Show Details link to full text
  Study

  EXPRESSION III

  Year

  2018

  Keywords

  • ovarian cancer
  • oncology

• PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study

  R. D. Hofheinz, C. Lange, T. Ecke, S. Kloss, B. Linsse, C. Windemuth-Kieselbach, P. Hammerer, S. E. Al-Batran

  PMID: 29305637 Show Details link to full text
  Study

  QoLiTime

  Year

  2018

  Keywords

  • cabazitaxel
  • prostate cancer
  • oncology

• Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.

  T.Biester, B. Aschemeier, M. Fath, M. Frey, M. F. Scheerer, O. Kordonouri, T. Danne

  PMID: 28417527 Show Details link to full text
  Study

  DAPA IIT179

  Year

  2017

  Keywords

  • dapagliflozin
  • type 1 diabetes

• The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

  B. A. S. Jaeger BAS, J. Neugebauer, U. Andergassen, C. Melcher, F. Schochter, D. Mouarrawy, G. Ziemendorff, M. Clemens, V. E. Abel, G. Heinrich, K. Schueller, A. Schneeweiss, P. Fasching, M. W. Beckmann, C. Scholz, T. W. P. Friedl, K. Friese, K. Pantel, T. Fehm, W. Janni, B. Rack

  PMID: 28586395 Show Details link to full text
  Study

  SUCCESS B

  Year

  2017

  Keywords

  • HER2
  • breast cancer
  • oncology

• Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study

  R. D. Hofheinz, C. Lange, T. Ecke, S. Kloss, B. Linsse, C. Windemuth-Kieselbach, P. Hammerer, S. E. Al-Batran

  PMID: 27618249 Show Details link to full text
  Study

  QoLiTime

  Year

  2017

  Keywords

  • cabazitaxel
  • mCRPC
  • QoL
  • oncology

• PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives

  J. Sehouli, E. I. Braicu, R. Chekerov

  PMID: 26941449 Show Details link to full text
  Study

  Year

  2016

  Keywords

  • PARP inhibitors
  • ovarian cancer
  • oncology

• Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

  L. Zimmer, J. Vaubel, P. Mohr, A. Hauschild, J. Utikal, J. Simon, C. Garbe, R. Herbst, A. Enk, E. Kämpgen, E. Livingstone, L. Bluhm, R. Rompel, K. G. Griewank, M. Fluck, B. Schilling, D. Schadendorf

  PMID: 25761109 Show Details link to full text
  Study

  Multibasket/DeCOG

  Year

  2015

  Keywords

  • uveal melanoma
  • ipilimumab
  • oncology

• Therapieinnovation: Der PARP Inhibitor Olaparib, Diagnostik und Therapie

  J. Pfisterer, F. Hilpert, A. du Bois

  PMID: Show Details link to full text
  Study

  Year

  2015

  Keywords

  • ovarian cancer
  • Olaparib
  • PARP inhibitors
  • oncology